ngiotensin II has been shown to exert a direct vasoconstrictor effect on the coronary arteries.1-3 In experimental animals, angiotensin converting enzyme (ACE) inhibition increases epicardial coronary artery diameter,4 whereas in humans, the ACE inhibitor enalaprilat has been shown to increase coronary blood flow in dilated cardiomyopathy when administered directly into the coronary circulation.5
However, after intravenous administration of enalaprilat in humans, absolute coronary blood flow does not increase, yet flow remains in excess of metabolic demand, despite a fall in perfusion pressure, suggesting primary coronary vasodilation mediated by ACE inhibition. 6 Although increased local kinin activity may in part mediate the vasodilator properties of ACE inhibitors,7 their predominant action is said to be via inhibition of circulating or local vascular ACE and, thus, decreased production of angiotensin II. 8 Catheter-based intravascular Doppler ultrasound has been used to measure coronary flow velocity, particularly in studies of coronary flow reserve,'6 and in the assessment of regional flow. '7 We have shown that a combined approach using both intravascular imaging and Doppler ultrasound in the coronary arteries permits simultaneous measurements of both luminal area and coronary blood flow velocity.18 Such an approach permits analysis of the differential effects of pharmacological agents on the epicardial coronary arteries and on the microcirculation and therefore is useful in studies of coronary vascular reactivity. '8"19 In the present study, in which we used intravascular two-dimensional and Doppler ultrasound to measure epicardial coronary dimensions and coronary flow velocity, respectively, we examined the effect of selective AT,-receptor blockade and ACE inhibition on the coronary circulation in vivo. To limit changes in loading conditions of the left ventricle, which greatly influence coronary blood flow,20 pharmacological agents were administered directly into the coronary circulation. We compared the vasodilator properties of AT,-receptor blockade by Losartan and ACE inhibition by enalaprilat with the coronary hyperemic response induced by adenosine. We then sought to investigate the interaction of Losartan-induced AT,-receptor antagonism with other potential coronary vasodilator mechanisms, i.e., release of endothelium-derived nitric oxide, release of vasodilator prostaglandin(s), and ,B-adrenoceptor stimulation.
Methods
Eleven mongrel dogs of either sex (eight males and three females; mean weight, 26.5 ±0.8 kg) were anesthetized with Innovar (0.04 mg/kg s.c.) and sodium pentobarbital (15 mg/kg i.v.), with additional doses of sodium pentobarbital as needed to maintain the level of anesthesia. They were mechanically ventilated with room air. Heart rate was monitored from the ECG, and blood pressure was monitored from a cannula placed in the right internal carotid artery. All studies conformed to the "Position of the American Heart Association on Research Animal Use" adopted November 11, 1984. 
Catheterization Procedures
Under fluoroscopic guidance, the left main coronary artery was cannulated via the transfemoral approach using an 8F canine guiding catheter (Advanced Cardiovascular Systems, Calif.). As 
Effect of Losartan on Coronary Artery Dimensions and Flow
Losartan caused dose-dependent increases in coronary cross-sectional area (to 9.5 ±0.8 mm2 at 1.6 mg/kg) and absolute coronary blood flow (to 151±36 mL/min at 1.6 mg/kg, p<0.01), as shown in Figures 1 and 2 . Average peak velocity rose significantly at the two highest doses, i.e., 1.6 (to 56±18 cm/sec, p<0.01) and 3.2 mg/kg. The peak effect was seen between 90 and 120 seconds, and the mean duration of the vasodilator response was 5.2±0.8 minutes. The ratio of systolic to diastolic time intervals remained unchanged with Losartan. No significant changes in systemic arterial pressure (93±6 mm Hg at 1.6 mg/kg) or heart rate (146±8 beats per minute at 1.6 mg/kg) were observed with any dose.
Effect of Enalaprilat on Coronary Artery Dimensions and Flow
Intracoronary enalaprilat (2.5 mg) did not influence mean arterial pressure (96±6 mm Hg) or heart rate (142±10 beats per minute) but caused a significant increase in coronary cross-sectional area and average peak velocity, resulting in an increase in coronary blood flow (Figure 3) . The higher dose (5 mg) caused a small additional vasodilation (cross-sectional area, 7.7±0.7 to 8.4±0.8 mm2; average peak velocity, 36±10 to 53±20 cm/sec; coronary blood flow, 82+25 to 122±41 mL/min; p<0.05) but no change in heart rate or blood pressure.
The magnitude of the increase in coronary blood flow with enalaprilat was significantly less than that with Losartan (F=4.767, p=0.04, from two-way ANOVA). The peak effect of enalaprilat was observed at 2.5-3 minutes after administration, and the mean duration of the vasodilator response was 5.9±1.1 minutes.
Effect ofAdenosine on Coronary Artery Dimensions and Flow
Intracoronary adenosine (6 mg) caused no change in coronary cross-sectional area, but resulted in a 3.7-fold increase in average peak velocity, so coronary blood flow increased from 78± 16 (p=0.014). The maximal effect of adenosine was seen at 40+5 seconds after administration. Mean arterial pressure (92+6 mm Hg) and heart rate (146+ 10 beats per minute) remained unchanged. Relative to adenosine, the maximal effect of Losartan (1.6 mg/kg) was 0.37, whereas the maximal effect of enalaprilat (5 mg) was 0.19 ( Figure 4 ).
Effect of Indomethacin on

Losartan-Induced Vasodilation
Indomethacin did not cause any change in blood pressure, heart rate, coronary artery cross-sectional area, average peak velocity, or volumetric blood flow. The vasodilator response to Losartan (1.6 mg/kg) was not altered by indomethacin, with regard to crosssectional area as well as average peak velocity.
Effect of Propranolol on Losartan-Induced Vasodilation
Propranolol reduced mean arterial pressure from 98±3 to 85+5 mm Hg (p =0.056) and heart rate from 150+ 10 to 119±4 beats per minute (p=0.02). Coronary artery cross-sectional area was unchanged, but average peak velocity decreased slightly from 34±11 to 27±2 cm/sec (p=0.08). The vasodilator response to Losartan (1.6 mg/kg) was not altered in any way by f3-adrenoceptor blockade.
Effect of L-NAME on Losartan-Induced Vasodilation
Intracoronary L-NAME (10-`M) caused a decrease in coronary artery cross-sectional area from 8.01±0.97 to 7.02±0.61 mm2 (p=0.016) but no significant change in average peak velocity, blood pressure, or heart rate. The vasodilator response to Losartan (1.6 mg/kg) in the epicardial coronary vessels was significantly reduced by L-NAME, but the increase in average peak velocity was not significantly affected. As a result of the attenuated effect of Losartan on the epicardial arteries, the increase in volumetric coronary blood flow tended to be reduced by L-NAME (p=0.08) ( Figure 5 ).
Discussion
The present study suggests There are at least three possible reasons for our finding of a difference between the effects of Losartan and enalaprilat. First, there may be other non-ACE biochemical pathways for conversion of angiotensin I to angiotensin II,8 so local angiotensin II generation might still occur despite administration of ACE inhibitors. In contrast, direct receptor antagonism would block the effect of angiotensin II irrespective of the pathway by which it is generated. This would account for greater vasodilation with Losartan. Second, circulating ACE may not have been completely inhibited at the dose of enalaprilat used in the present study. However, the occurrence of substantial dilation of resistance vessels at this dose argues against this explanation. Furthermore, at the 5-mg dose, the effective concentration of enalaprilat in the coronary arteries during the first minute after injection is approximately i0`M (at an assumed flow rate of 100 mL/min). This concentration has been previously shown to completely inhibit cardiac ACE activity in isolated rat hearts.31 Third, there may be a lower concentration of ACE in the conductance vessels than in resistance vessels, resulting in a greater effect of ACE inhibition further downstream. Precedents exist for variability in vascular renin-angiotensin system activity depending on blood vessel size. For example, in spontaneously hypertensive rats, topical application of saralasin to the microvasculature resulted in selective dilation of third-and fourth-order arterioles.32 Local vascular renin-angiotensin system activity has also been observed in conduit vessels: In humans, ACE inhibitors increase the compliance and diameter of large peripheral arteries, even at doses that are without a systemic hypotensive response.3334 ACE is known to occur in coronary arteries,35 but its physiological significance is 
